On March 7, 2025, Senti Biosciences appointed Feng Hsiung as a director and increased the board size to seven members; he will receive options for 43,900 shares and an annual cash retainer of $35,000. The company also approved an amended equity incentive plan increasing shares by 4.3 million and granted stock options to executives, including 1,927,073 shares to CEO Timothy Lu.